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Abstract
AIM: To assess the efficacy and safety of Saccharomyces
boulardii (S. boulardii ) in acute watery diarrhoea and its
role in reducing the frequency of episodes of diarrhoea
in subsequent two months.
METHODS: Children from 2 mo to 12 years of age, with
acute diarrhoea were selected according to inclusion criteria and randomised in S. boulardii group (treated with
ORS, nutritional support and S. boulardii , 250 mg bid)
and in control group (treated with ORS and nutritional
support only). Active treatment phase was 5 d and each
child was followed for two months afterwards. Frequency
and consistency of stools as well as safety of drug was
assessed on every visit. A comparison of two groups was
done in terms of number of diarrhoeal episode in subsequent two months.
RESULTS: There were fifty patients in each group. Baseline characteristics such as mean age and the average
frequency of stools were comparable in S. boulardii and
control group at the time of inclusion in the trial. By d 3
it reduced to 2.7 and 4.2 stools per d respectively and by
d 6 it reduced to 1.6 (S. boulardii Group) and 3.3 (control
group). The duration of diarrhoea was 3.6 d in S. boulardii group whereas it was 4.8 d in control group (P =
0.001). In the following two months, S. boulardii group
had a significantly lower frequency of 0.54 episodes as
compared to 1.08 episodes in control group. The drug
was well accepted and tolerated. There were no reports

of the side effects during treatment period.
CONCLUSION: S. boulardii significantly reduces the frequency and duration of acute diarrhoea. The consistency
of stool also improves. The drug is well-tolerated.
© 2006 The WJG Press. All rights reserved.
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INTRODUCTION
Acute infectious diarrhoeal disease is a worldwide problem
with over two million deaths each year. Diarrhoeal diseases
are a leading cause of childhood morbidity and mortality
and over 200 000 children die every year (600 deaths per
day) in Pakistan. Repeated episodes of diarrhoea lead to
under-nutrition. In Pakistan, every child gets, on average,
5-6 episodes of diarrhoea per year.
Last couple of decades has seen greater understanding of pathogenesis and simple methods of management
of diarrhoea. Various modalities of interventions have
been used in different parts of the world to improve the
diarrhoeal mortality and morbidity which include oral
rehydration salt (ORS), cereal based ORS, antibiotics,
anti-diarrhoeals, antispasmodics and anti-emetics. Some
of these modalities later proved to have variable harmful
effects. These harmful effects include worsening of diarrhoea, increased duration of diarrhoea, adverse effects on
gut motility leading to paralytic ileus. In addition, there are
other systemic untoward effects[1,2].
Gastrointestinal disease is often a consequence of
a myriad of factors, which disturb the bowel’s complex
ecosystem. The concept of modulating bacterial activities,
directed towards improving gut microbial function, has a
long history. The use of yoghurt (as probiotic) in the treatment of diarrhoea has been known for a long time. It is
now recognised that the most frequently used method of
influencing the gut flora composition is that of probiotwww.wjgnet.com
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ics. A probiotic is a living micro organism administered to
promote the health of the host by treating or preventing
infections owing to strains of pathogens[3]. Bio-therapeutic
agents are defined as probiotics registered as drugs.
The modern view of probiotic therapy derives from
the concept of a well functioning gut barrier and a normal
balanced microbiota.
Numerous probiotic agents have been studied for
the management of diarrhoeal disease. In particular, the
prevention and management of acute viral diarrhoea,
the treatment of recurrent Clostridium difficile diarrhoea,
as well as the control of antibiotic-associated diarrhoea
seem to be areas of significant potential benefit. A few
agents, including Lactobacillus GG, Lactobacillus reuteri, and
Saccharomyces boulardii (S. boulardii), seem to be promising
agents for the amelioration of the course of acute
diarrhoea in children when used therapeutically[4]. Amongst
these, all are bacteria except S. boulardii, which is yeast.
S. boulardii is a non-pathogenic yeast first isolated from
lychee fruits in Indonesia and used first in France to treat
diarrhoea, in the beginning of the 1950s. A lyophilised
form is in clinical use in Europe, Asia, Africa, and Central
and South America.
Preclinical and experimental studies of S. boulardii
have demonstrated an anti-inflammatory, antimicrobial,
enzymatic, metabolic and antitoxinic activity. S. boulardii
secretes a 54-KDa protease which has been shown to
neutralize certain bacterial toxins; S. boulardii is also able to
stimulate an immune response in the intestinal mucosa. It
has a trophic effect by enhancing the metabolic function
of the mucosa. S. boulardii releases polyamines, which are
implicated in stimulating the enzymatic activity of the
colonic mucosa[3,5].
Based on our previous experience of use of S. boulardii
in the treatment of diarrhoea, this study was undertaken
to assess the efficacy of S. boulardii in the treatment of
diarrhoea and reoccurrence of diarrhoea in subsequent
two months.

MATERIALS AND METHODS
Patients
This randomised controlled clinical trial was carried out at
Kharadar General Hospital, Karachi, catering to the needs
of approximately one million population and situated in
the middle and low-income community. An informed
consent was obtained from parent/guardian of every child
included in the trial. The children from 2 mo to 12 years
of age presenting with acute watery diarrhoea of mild
to moderate severity, fulfilling the inclusion criteria were
included in this trial.
Children with severe inter-current illnesses, severe diarrhoea and dehydration requiring hospitalisation and intravenous therapy, presenting with temperature above 38.5℃,
who were treated by any other anti-diarrhoeal/antibiotics
in last 24 h as well as severely malnourished children were
excluded from the trial. At inclusion, stool specimen was
sent for bacterial culture and sensitivity as well as for Rota
virus detection.
The study population of 100 children was randomised
into two groups. In S. boulardii group, patients were
www.wjgnet.com
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Table 1 Baseline characteristics
Patient characteristics
Age (mo)
Mean
SD
Weight (kg)
Mean
SD
Sex
Female
Male
Stool culture/Sensitivity
Bacteria isolated
Not isolated
Rota virus
Positive
Negative

S. Boulardii
(n = 50)

Control
(n = 50)

P value

18.3
20.33

26.01
23.37

0.08

8.2
3.58

9.15
4.13

0.224

50%
50%
26%
74%

16%
84%

50%
50%

1

12%
88%

0.125

20%
80%

0.795

managed by WHO-CDD protocol[6] plus S. boulardii (250
mg bid) administered orally diluted in water or other semisolid food. The product was manufactured by Hilton
Pharma (Pvt) Ltd. under the license of Biocodex, France.
In the control group patients were managed by WHOCDD protocol only. The active treatment period was 5 d.
Treatment of the subsequent episodes of diarrhoea was at
the discretion of the treating physician.
All study participants were examined on d 0 (inclusion
day), and followed up on d 3 and d 6 during active
treatment phase and ever y month for two months
thereafter for observation.
The first visit data collection included date of onset of
diarrhoea, previous treatment (where applicable), weight
of child, number and consistency of stools, vomiting,
body temperature, sign of dehydration and any other data
by clinical examination. The second visit information
variables included date of stoppage of diarrhoea in case
of inter-current recovery, weight of child, daily record
of frequency and consistency of stools, tolerance and
acceptability of treatment. Similarly on third visit, date of
stoppage of diarrhoea in case of inter-current recovery,
weight of child, daily record of frequency and consistency
of stools, tolerance and acceptability of treatment were
recorded in the study record forms.
A monthly obser vational follow-up data for two
months included weight of child at monthly interval and
any new episodes of diarrhoea in both the groups.
Statistical analysis
For statistical analysis, t-test was applied to measure the
variation in means. P < 0.05 was taken as significant.

RESULTS
One hundred patients were analysed in the study, fifty
patients in each group. Patient baseline characteristics
in control and study groups were comparable (Table 1).
Bacteria were isolated in 26% and 12% of the S. boulardii
and control groups respectively while Rota virus detection

Billoo AG et al. Probiotic on diarrhoea

			

Table 2 Mean numbers of stools and duration of diarrhoea
S. boulardii

Control P value

Mean number of stools reported on d 0

9.5

8.8

0.37

Mean number of stools reported on d 3

2.8

4.4

0.01

Mean number of stools reported on d 6

1.6

3.3

0.001

Duration of diarrhoea (d)

3.6

4.8

0.001

Table 3 Number of episodes of diarrhoea
S. boulardii

Control

No. of episodes at 1 mo

0.2

0.64

P value
0.001

No. of episodes at 2 mo

0.32

0.56

0.04

Table 4 Weight gain
Group
% increase in wt. at 1 mo S. boulardii
Control
% increase in wt. at 2 mo S. boulardii
Control

% of mean weight gain P value
4.4
4.2

0.902

9.9
6.2

0.067

revealed 16% and 20% positive for test and control group
respectively.
On d 3 and d 6, there was a significant reduction in reported number of stools in S. boulardii group as compared
to the control group. The mean duration of diarrhoea was
3.5 d in S. boulardii group and 4.8 d in the control group (P
= 0.001) (Table 2).
Follow-up for the next two months also revealed interesting results. Mean numbers of episodes of diarrhoea
by the end of two months, were 0.56 in control group as
compared to 0.32 in S. boulardii group, which is almost half
of that of control group (Table 3).
S. boulardii was well accepted and tolerated by the children and there were no reports of any side effects during
the study period.
Table 4 also shows mean weight gain in both groups at
mo 1 and 2. Although the difference of gain between the
two groups has not reached statistical significance, the percentage of average increase in the experimental group was
9.9% as compared to 6.2% in the control group.

DISCUSSION
There are over 10 9-12 bacteria per gram of faeces and
about 400 different species, more than 10 times the
human cells[7]. The intestinal flora is intimately associated
with the organ which contains it and with which it forms
an ecosystem. Equilibrium within this ecosystem is
essential to good health of the individual. It influences
the structure, motility, physical and chemical conditions
of intestinal tract, metabolic and enzyme activity of
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mucosa and establishment and maturation of immune
system. Finally and above all, the intestinal microbial flora
forms a true resistance to colonisation of digestive tract
by pathogenic microorganisms. Disruption of intestinal
ecosystem occurs in many pathological situations such
as infectious diarrhoea or diarrhoea and colitis linked to
antibiotic treatment.
Despite awareness about preventive aspects of diarrhoea it remains one of the leading causes of morbidity
and mortality in children, because of lack of clean water
supply and sanitation.
Search for newer, less harmful agent is continued. Biological agents ("biotherapeutic agents" or "probiotics")
have been used to treat a variety of infections, most notably infections of mucosal surfaces such as the gut and vagina. These biotherapeutic agents include certain bacteria
and the yeast S. boulardii. Given orally, S. boulardii seem to
be promising agents for the amelioration of the course of
acute diarrhoea in children[8].
The current study was based on our previous clinical
observation, which revealed that children treated with S.
boulardii had a decreased number of episodes of diarrhoea
in following months.
This study verified our previous observation, as there
was a 50% reduction in the number of episodes of diarrhoea in the treatment group as compared to control
group (Table 2).
This study also showed a significant improvement in
frequency and consistency of stool and reduction in duration of illness in patients who were given S. boulardii along
with WHO-CDD protocol.
Several studies of S. boulardii have been done in children and adults in the treatment of acute diarrhoea[9]. The
results of our studies are consistent with some of these
studies. However, the current study is the first one to observe the reduction in number of episodes of diarrhoea in
the post-treatment follow-up period of two months. Stimulation of local immunity, as demonstrated by the increase
of IgA, together with the enhancement of the trophic
activity of the mucosa (through the release of polyamines)
by S. boulardii may, at least in part, explain the long term
effect of the yeast.
A meticulous follow-up of the patient resulted in very
good compliance. No side effects were observed during
the active treatment period with the use of S. boulardii.
McFarland et al also highlight the safety profile in their
review on S. boulardi[10].

CONCLUSION
Based on our experience of this trial we conclude that S.
boulardii is a useful and welcome addition to the treatment
of acute diarrhoea in children. S. boulardii reduces the
frequency of stool, and duration of illness. It also reduces
the number of episodes of diarrhoea by 50% in the
subsequent period of two months.
Though this is the first study of its kind in Pakistan, we
are of the opinion that multicenter double blind placebo
controlled trials need to be conducted to confirm our
observations. Investigators have been using probiotics as

www.wjgnet.com
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prophylaxis in childhood infection whereby it has been
shown to reduce the rate of infection[7,11].
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